Search Results
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
lymphoma (LBCL), including patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC and B-cell/lymphoma 2 (BCL2) and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B), T-cell/histiocyte-rich large B-Cell lymphoma (TCHR LBLC),
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
lymphoma (LBCL), including patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), high-grade B-Cell lymphoma (HGBL) with MYC and B-cell/lymphoma 2 (BCL2) and/or BCL6 rearrangements, follicular lymphoma grade 3B (FL3B), T-cell/histiocyte-rich large B-Cell lymphoma (TCHR LBLC),
More news about: AbbVie
Jun 25, 2026, 10:51 ET Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
address TKI therapeutic resistance in EGFR-mutant NSCLC. RC220 gives us the opportunity to explore whether targeting G4-DNA and RNA structures, including MYC-associated growth pathways, can delay EGFR TKI resistance arising and support a new therapeutic combination for patients treated with osimertinib. We
More news about: Racura Oncology Limited
Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
opaganib as a potential add-on to chemotherapy, showing an ability to directly destabilize a key oncogenic driver of neuroblastoma and other solid tumors, n-Myc, through increased ceremide production enhancing programmed cancer cell death (apoptosis)," said Dr. Mark Levitt, Chief Scientific Officer
More news about: RedHill Biopharma Ltd.
May 15, 2026, 07:06 ET Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent silencing of the important cancer growth regulator MYC.About Racura OncologyRacura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence
More news about: Racura Oncology
May 06, 2026, 07:00 ET (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
(E,E)-bisantrene directly binds and stabilizes G4 DNA structures within the c-MYC gene promoter region, resulting in potent suppression of c-MYC expression and broad cytotoxic activity in a wide range of cancer models.[1][2]The MYC protein functions as a master regulator of gene expression, governing
More news about: Racura Oncology
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
opaganib may enhance the therapeutic efficacy of the oxaliplatin + doxorubicin (OXDOX) chemotherapy combination in high-risk NB by directly destabilizing n-Myc, a key oncogenic driver of neuroblastoma and other solid tumors, through increased ceremide production enhancing programmed cell death (apoptosis) in
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 07:00 ET Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
gilteritinib, and azacitidine.Across models, combinations were associated with downregulation of proliferative programs, including MYC target genes, E2F targets, and G2/M checkpoint signatures, together with enrichment of p53-associated stress response and apoptosis pathways.Together,
More news about: Actinium Pharmaceuticals, Inc.
Apr 15, 2026, 09:04 ET Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase
its neurodegeneration collaboration with Daiichi Sankyo, the company is advancing an internal pipeline including an oral small molecule inhibitor of c-Myc for solid tumors. Wayfinder Biosciences was founded by RNA scientists from the University of Washington and is based in Seattle.
More news about: Wayfinder Biosciences, Inc.
Feb 19, 2026, 08:00 ET Ten63 Therapeutics Closes Strategic Financing, Bringing Total Funding to More Than $45M to Scale the Next-Generation of Artificial Intelligent Drug Discovery
such program focuses on Myc, one of the most-studied oncogenes, which has long been considered undruggable and is believed to drive 70% of all cancers. Despite hundreds of attempts spanning 40 years, it remains elusive. With the mathematical breakthroughs behind BEYOND, Ten63 has Myc-targeting therapeutics
More news about: Ten63 Therapeutics
Jan 28, 2026, 17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight
human cancers exhibit elevated Myc expression, one of the most critical yet historically "undruggable" oncogenic drivers, PC-002 is designed to inhibit the DUB that stabilizes Myc in cancer cells. This results in selective Myc degradation and apoptosis induction in Myc-dependent tumors, positioning PC-002
More news about: DelveInsight Business Research, LLP
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
2Phase 1b/2 Trial of Pidnarulex in MYC Aberrant LymphomaUp to 50 subjectsPhase
More news about: Senhwa Biosciences, Inc.
Dec 15, 2025, 08:00 ET Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
findingsTranscriptomic analyses showed that (Z)-endoxifen reverses multiple mutant ESR1–associated oncogenic pathways (e.g., estrogen response, E2F, Myc) while restoring beneficial programs (oxidative phosphorylation, p53), highlighting its therapeutic potential for ER+ / ESR1 mutant breast cancerA
More news about: Atossa Therapeutics Inc
Dec 03, 2025, 10:56 ET Franchise Equity Partners przejmuje IMO Car Wash od Driven Brands
detalicznym w Stanach Zjednoczonych na Wielką Brytanię, Europę i inne regiony".Pod kierownictwem FEP firma IMO skoncentruje się na zwiększeniu liczby myć, poprawie jakości obsługi klienta oraz rozwijaniu strategicznych partnerstw detalicznych. IMO utrzymuje silne relacje z detalistami w Wielkiej Brytanii
More news about: Franchise Equity Partners
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
25-2034) Developing artificial intelligence-based transcriptomic signature for the diagnosis of dark zone lymphoma in patients without MYC gene rearrangement (ABSTRACT 25-7855) A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation
More news about: Hackensack Meridian John Theurer Cancer Center
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
understood as a genetically defined disease (most cases driven by bi-allelic loss of SMARCB1; some by SMARCA4), with distinct molecular subgroups (e.g., TYR/SHH/MYC). That molecular clarity is making targeted and subgroup-specific drug development feasible. Improved
More news about: DelveInsight Business Research, LLP
Oct 14, 2025, 17:31 ET Anaplastic Astrocytoma Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
blood-brain barrier, where it downregulates short-lived, anti-apoptotic oncogene proteins such as Myc. It is being developed for high-grade glioma and diffuse intrinsic pontine glioma, both brain cancers associated with Myc overexpression. A Phase Ib clinical trial conducted by the U.S. National Cancer Institute
More news about: DelveInsight Business Research, LLP
Oct 08, 2025, 08:01 ET TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
siRNA-based modulator of PD-L1 TTX-RIGA, RNA-based agonist of RIG-I TTX-siMYC, RNA-based inhibitor of c-MYC About the Acquisition and Financing Pursuant
More news about: TransCode Therapeutics, Inc.
Sep 24, 2025, 11:13 ET Children's Hospital of Philadelphia Researchers Find Combination of Diet and Medication Reprograms Fatal Childhood Tumors
Preclinical study offers a potential new approach to the treatment of neuroblastoma and other MYC driven cancers PHILADELPHIA, Sept. 24, 2025
More news about: Children's Hospital of Philadelphia